Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

NCT06667154 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer, Nonsmall Cell
Non-Small Cell Lung Cancer NSCLC

Interventions

DRUG: Low-dose nivolumab combined with platinum-based doublet chemotherapy

Sponsor

Aline Fusco Fares, MD

Collaborators

[object Object]